Scroll To Top
Search by Speciality

RIMS 2013: Rehabilitation in Multiple Sclerosis 18th Annual Conference

Bella Center # | Copenhagen, DENMARK
From 220 to 620 EUR
Event Preview
This event
is Finished
Title: RIMS 2013: Rehabilitation in Multiple Sclerosis 18th Annual Conference
Specialty: , Neurology
Dates: From Oct, 2, 2013 to Oct, 5, 2013
Location: Copenhagen, DENMARK
Type: Conference, Course
Registration Cost: From 220 to 620 EUR
Event Tools
  • Add to Favorites
  • Claim this event
Add to my Calendar
  • Scientific Programm
  • Online registration
  • Exhibition floorplans
  • Sponsorship &
    Exhibition consensus
  • Virtual Booths
Weather Info (monthly averages) Max Temperature: C / F Min Temperature: C / F The above data in our Weather Info table are temperature predictions for the date of the medical event for Copenhagen, Denmark.
General Info
Event Venue:

Bella Center #

Copenhagen, DENMARK
THE BELLA CENTER GROUP Bella Center is a fully modern trade fair and convention centre that is capable of hosting all types of events: trade fairs & exhibitions, large & small meetings, international conventions, parties - everything is possible.   The entire centre is equipped with broadband internet access and all meeting rooms feature wireless network capabilities. We always have the latest IT and audiovisual technology, as well as other technical equipment.   If you require a permanent showroom in the fields of fashion or interior design, or a standard office space, we can also meet these needs.  
TRADE FAIR- AND EXHIBITION CENTER Bella Center arranges a wide range of large and small fairs and exhibitions every year. CONGRESS CENTER Meetings and congresses of all sizes are held at Bella Center. BELLA SKY COMWELL HOTEL COPENHAGEN In May 2011 Bella Sky Comwell hotel opened. The hotel has 812 rooms, a number of meeting rooms plus restaurants and sky bar.   HOTEL CROWNE PLAZA COPENHAGEN TOWERS In January 2014 Hotel Crowne Plaza Copenhagen Towers in Ørestad - one of the leading  sustainable hotels in Denmark - became part of the Bella Center Group. CIFF SHOWROOMS The first and second floors of Bella Center feature permanent showrooms for fashion, shoes and accessories. The area is reserved for invited buyers. INTERNATIONAL HOUSE A part of Bella Center is its centrally located office hotel, featuring all modern facilities and offices of all sizes. FORUM COPENHAGEN Located close to Copenhagen's centre, Forum became a subsidiary of Bella Center in 1997 and operates today as an integrated part of the group. A wide range of events are held at Forum, including concerts, exhibitions, banquets and much more.
Visit the Venue to read more
Transportation Guide:


Copenhagen Airoprt is well connected to many destinations within Europe and overseas. The Bella Center is just a
10 minute taxi drive from the airport (estimated price: DKK 150-200).
Further, a regional train runs from the airport to Ørestad Station.


For information on departure and arrival times, please refer to the airport’s website.

Please note that no official shuttles are provided between the airport and the Bella Center. Delegates are kindly requested to make their own way from / to the airport.




It takes about 10 – 15 minutes taxi drive to get to the Bella Center from Copenhagen’s central train station. Alternatively, you can also get to the Bella Center by taking bus line 30 from the train station (20-25 minutes). All regional trains also stop at Ørestad Station, where you can transfer to the Metro.


For further information, timetables and ticket reservation please refer to DSB.




A taxi from Bella Center to the city centre costs about DKK 200, from Bella Center to Copenhagen Airport about
DKK 150-200. 





The metro station ”Bella Center” is located next to the Bella Center’s East Entrance. The main entrance to the congress is signposted from the station. Metro line M1 runs between Vanløse and Vestamager (West Amager).


More information and timetables are available on




The following bus lines connect the Bella Center to various destinations in Copenhagen:


Bus line 30: Runs between Vesterport Station (via the central station) and Bella Center.

Bus line 4A: Runs from Svanemøllen Station to Sundbyvester Plads via Valby Station and Sjælør Station.

Bus line 250S: Runs from Buddingevej via Forum Station and Copenhagen Central Station to Bella Center.

Information on bus schedules can be found on



Public Transportation Tickets

ECTRIMS has negotiated day tickets for the Copenhagen public transportation network for a very good price. Tickets can be purchased at app. Euro 10.- for the first 2 days and Euro 5.- for every following day. The normal ticket price is app. Euro 17.- per day. Please note that exact prices vary with the exchange rate.


Please click here if you would like to order transportation tickets. The electronic tickets will be sent to you by SMS one day before the day you purchased the ticket for.

Using this link will let you leave the ECTRIMS website. The linked site is not under the control of ECTRIMS and ECTRIMS shall not be responsible for the contents of this site. The link is only available for your convenience.

Event Overview
Welcome message:

Dear Colleagues and Friends,

welcome to the 29th Congress of the European Committee for Research and Treatment in Multiple Sclerosis (ECTRIMS) and the 18th Annual Conference of Rehabilitation in MS (RIMS) in Copenhagen, Denmark, 2– 5 October, 2013.

This is the second time that Copenhagen will host the ECTRIMS Congress. In 1996, approximately 700 participants attended the 12th ECTRIMS congress in Copenhagen and this year we expect almost 10 times as many people.

In 1996, a new era of MS therapy had begun in Europe with the introduction of INF-b treatment and since then several other and more effective therapies have been introduced to prevent disease activity and progression in MS. We are only at the beginning of this era and from 2013 and the following years new therapeutic possibilities will emerge to benefit people with MS. Along the same line rehabilitation has been enhanced with implementation of new evidence-based programmes. The ultimate aim is a highly individualized treatment and rehabilitation of patients in all stages of MS.

Multiple sclerosis research in Copenhagen dates many decades back and the late professor Torben Fog was a pioneer in the field of MS pathology, clinical course and therapy. In 1973, he was involved in immune treatment of MS with transfer factor and in 1980 one of the first to try treatment with interferon in patients with MS. He co-authored the first publication that linked the major histocompatibility system (HLA) to susceptibility of MS and he developed an elaborate scoring system for neurological impairment in MS. In addition, he meticulously studied thin sections of MS plaques. Following their shape and course with direct drawings of each section he described that plaques consistently followed the course of the venous system. His observations have, unwarrantedly, been used to set the background for chronic cerebrospinal venous insufficiency (CCSVI). We have tried to follow his footsteps and currently the Danish MS research is making rapid strides in both basic and clinical MS research.

The ECTRIMS Scientific Committee, the RIMS Executive Board and the Local Organizing Committee are very proud of the programme, and are confident that you will experience a congress with high scientific quality in basic, therapeutic and rehabilitation aspects of MS.

Copenhagen is usually very pleasant in the beginning of October and you will have the opportunity to enjoy its charms. Copenhagen has several Michelin starred restaurants, including “Noma” appointed as the world best restaurant 3 years in a row, and “Geranium” with the highest ranking chef in the world. You may also enjoy the small restaurants and bars in “Nyhavn”, “Tivoli” and the old town centre with one of Europe’s largest pedestrian zones.

The venue of the congress is the modern Bella Centre located less than 10 minutes from the airport and the city centre by train or metro.

We hope to see you for a successful and exiting meeting that will present the most recent advances in the research of the pathogenesis, treatment and rehabilitation in MS.


P. Soelberg Sørensen
Chair ECTRIMS 2013

P. Feys
RIMS President

M. Trojano
ECTRIMS President

D. Miller
ECTRIMS Secretary



Amato, Maria Pia


Banwell, Brenda
Bar-Or, Amit
Bates, David
Benedict, Ralph
Blinkenberg, Morten
Boyko, Alexey
Brinar, Vesa
Brochet, Bruno


Calabresi, Peter
Ciccarelli, Olga
Clanet, Michel
Cohen, Jeffrey
Comabella, Manuel
Comi, Giancarlo
Compston, Alastair
Confavreux, Christian
Costello, Fiona


Dalgas, Ulrik
De Jager, Philip
de Sèze, Jérôme
De Stefano, Nicola
Deisenhammer, Florian
Devos, Hannes
Dyrby, Tim


Ebers, Georg
Edan, Gilles
Elovaara, Irina
Engelhardt, Britta
Enzinger, Christian


Feinstein, Anthony
Feys, Peter
Finlayson, Marcia
Finsen, Bente
Fox, Robert
Fredrikson, Sten
Friedemann, Paul
Fugger, Lars


Ghezzi, Angelo
Giovannoni, Gavin
Gold, Julian
Gold, Ralf
Green, Ari


Hämäläinen, Päivi
Harbo, Hanne
Havrdova, Eva
Heesen, Christoph
Hemingway, Cheryl
Hemmer, Bernard
Henze, Thomas
Hillert, Jan
Holder, Graham
Houtchens, Maria


Illés Zsolt, Laslow


Jacob, Anu


Kappos, Ludwig
Kerschensteiner, Martin
Khalil, Michael
Kieseier, Bernd
Kira, Jun-Ichi
Koch-Henriksen, Nils
Kos, Daphne


Lassmann, Hans
Liblau, Roland
Lindberg, Raija
Lubetzki, Catherine
Lublin, Fred
Lycke, Jan


Marcias, Miguel Angel
Matthews, Vicky
Meinl, Edgar
Miller, Aaron
Miller, Ariel
Miller, David
Milonas, Ioannis
Montalban, Xavier
Motl, Robert
Myhr, Kjell-Morten


Neuteboom, Rinze


O'Connor, Paul
Olsson, Thomas
Op`t Eijnde, Bert
Oreja-Guevara, Celia
Oturai, Anette
Owens, Trevor


Papathanasiou, Eleftherios S.
Pedersen, Oluf Borbye
Pelletier, Daniel
Petzold, Axel
Polman, Chris
Prat, Alexandre


Ravnborg, Mads
Rocca, Maria
Romberg, Anders
Rovira, Alex


Sawcer, Stephen
Sellebjerg, Finn
Sena, Armando
Siebner, Hartwig
Siva, Aksel
Soelberg-Sørensen, Per
Solari, Alessandra
Solaro, Claudio
Sormani, Maria Pia
Stadelmann, Christine
Stankoff, Bruno


Teunissen, Charlotte
Thompson, Alan
Tintore, Mar
Trapp, Bruce
Trojano, Maria


Uitdehaag, Bernd


Valls-Sole, Josep
Vermersch, Patrick
Vincent, Angela
Voskuhl, Rhonda
Vukusic, Sandra


Wattjes, Mike
Wekerle, Harmut
Wolinsky, Jerry


Zamvil, Scott
Ziemssen, Tjalf
Zipp, Frauke

Courses / Workshops within the event

Teaching Courses Programme

08.30 – 10.00

Teaching Course 1Meet the Professors: Interactive Case Discussion

A. Miller (New York, US)
D. Bates (Newcastle, UK)

Interactive case discussion

A. Miller (New York, US)

Interactive case discussion

D. Bates (Newcastle, UK)
In this programme, two experienced MS clinicians, from either side of the Atlantic Ocean, will utilize an audience response system to engage the audience in an interactive programme that reviews several clinically important issues regarding MS and related demyelinating disorders. As a result of the complexities of MS and the availability of many new therapeutic agents, few decisions today are “black and white”. This course should enable the participants to see the various shades of grey that can lead to more informed decision-making. 
08.30 – 10.00

Teaching Course 2Paediatric MS

B. Banwell (Philadelphia, US)
C. Hemingway (London, UK)

Differences between paediatric and adult MS

B. Banwell (Philadelphia, US)

Relapse activity and progression in pediatric multiple sclerosis

C. Hemingway (London, UK)

Treatment of paediatric MS

M. Tardieu (Paris, FR)
This course will explore in three 30 minute sessions some of the significant differences between paediatric and adult onset MS. It will look first at the defintion of paediatric MS, the different presentations seen in early onset paediatric MS and compare these seen in later onset paediatric MS and the main differential diagnosis to consider in young people. It will also review the difference in the relapse activity and rate of progression in paediatric MS and compare this to what is known in adults with MS . The differences seen in the investigations and imaging will also be discussed. The final presentation will review both first and second line treatments used in paediatric MS, what we know about the efficacy and safety of these treatments and the need for international studies in the use of the ever increasing number of new treatments in MS in those with onset under 18 years of age.

08.30 – 10.00

Teaching Course 3How do I choose the correct disease-modifying treatment for my MS patient?

B. Kieseier (Dusseldorf, DE)
R. Fox (Cleveland, US)

To treat or not to treat CIS and RRMS

S. Fredrikson (Stockholm, SE)

Choosing the right treatment for the individual patient

R. Fox (Cleveland, US)

When and how should treatment be switched or escalated?

B. Kieseier (Dusseldorf, DE)
The current spectrum of disease-modifying therapies for relapsing MS has expanded in recent years. Most therapies differ from one another in either mechanism of action, mode of administration, side-effect profile and, possibly, their clinical benefits to patients. Some treatments are modestly effective and very safe, while others may be more effective but have some risks of complications. The MS neurologist is challenged to identify the optimal treatment for individual patients. Whereas personalized efficacy has eluded us, personalized risk stratification has become increasingly important in guiding treatment recommendation. This teaching course will discuss some of the issues that can be considered when making treatment recommendations in this new treatment era.
08.30 – 10.00

Teaching Course 4Clinically isolated syndromes (CIS)

O. Ciccarelli (London, UK)
M. Tintoré (Barcelona, ES)

Definition of CIS: adults versus children

D. Pelletier (New Haven, US)

What are the clinical, CSF, and MRI predictors of conversion to MS?

O. Ciccarelli (London, UK)

How can we treat and manage CIS patients?

M. Tintoré (Barcelona, ES)
Clinically Isolated Syndrome is the first manifestation of multiple sclerosis in the majority of adults and children. The aim of this Teaching Course is to review and discuss the challenges posed by the diagnosis, prediction of outcome and clinical management of patients with CIS. In particular, we will review the similarities (and differences) of clinical characteristics of CIS between children and adults, and discuss the risk factors used in clinical practice to predict the evolution from CIS to MS. We will also review not only the treatments that delay the clinical onset of MS but also those which are currently being tested in clinical trials.
08.30 – 10.00

Teaching Course 5Symptomatic management in multiple sclerosis

C. Oreja-Guevara (Madrid, ES)
A. Ghezzi (Gallarate, IT)

Spasticity and gait impairment

C. Oreja-Guevara (Madrid, ES)

Bladder, sexual and bowel dysfunction

A. Ghezzi (Gallarate, IT)

Pain, depression and fatigue

C. Solaro (Genoa, IT)
Many of these MS-related symptoms are frequently ignored in assessments of disease status and are often not considered to be associated with the disease. Research into how such comorbidities and symptoms can be diagnosed and treated within the MS population is lacking. The early recognition and treatment of these alterations can improve the quality of life of patients. In this course, we would like to review these symptoms of MS like spasticity, bladder, bowel and sexual disfunction, pain, depression and fatigue and to learn about the treatments for these alterations.
08.30 – 10.00

Teaching Course 6Management of the pregnant MS patient

I. Elovaara (Tampere, FI)
M. Houtchens (Harvard, US)

Modulatory effects of pregnancy in multiple sclerosis

I. Elovaara (Tampere, FI)

Breast-feeding, postpartum and prepregnancy disease activity in multiple sclerosis

R. Neuteboom (Rotterdam, NL)

Therapeutic consideration during pregnancy

M. Houtchens (Boston, US)
Since multiple sclerosis predominantly affects women of childbearing age, the issues of conception, pregnancy, delivery and breastfeeding become of significant importance to patients and treating physicians. The risks and benefits of ongoing therapies for the health of both the mother and the foetus must be considered. The purpose of this course is to review the evidence on modulatory effects on pregnancy in relapsing-remitting MS and long-term disease course. The risks and benefits of disease-modifying treatments around conception and during pregnancy as well as management of MS relapse during pregnancy and questions related to breastfeeding will be addressed.
08.30 – 10.00

Teaching Course 7Electrodiagnostic examinations in MS

E.S. Papathanasiou (Nicosia, CY)
J. Valls-Sole (Barcelona, ES)

Visual electrophysiology (VEP, ERG)

G. Holder (Moorfields, UK)

Brainstem and other reflexes

J. Valls-Sole (Barcelona, ES)

Evoked potentials

E.S. Papathanasiou (Nicosia, CY)
Electrodiagnostic examinations are very powerful tools to document nervous system function. They show unique quantitative data on functional aspects of central and peripheral neurological disorders. Although it is almost universally accepted that electrodiagnostic examinations are not necessary for MS diagnosis, they can still provide information on important aspects of the disease, such as with understanding pathophysiological mechanisms, identifying if new symptoms are due to progression of the disease or to the presence of a comorbid condition, and assessing the effects of therapeutic measures. The audience will be shown findings in various clinically relevant neurophysiological tests in MS.
10.00 – 10.30

Coffee break

10.30 – 12.00

Teaching Course 8Differential diagnoses and diagnostic dilemmas in MS

P. Vermersch (Lille, FR)
J-I. Kira (Fukuoka, JP)

Diagnostic approach to multiple sclerosis

P. Vermersch (Lille, FR)

Neuromyelitis optica and related disorders

J-I. Kira (Fukuoka, JP)

Autoimmune rheumatologic disorders and antibody mediated encephalopathies

J. Kitley (Oxford, UK)
Diagnostic approach to multiple sclerosis (MS) includes clinical and paraclinical assessments emphasizing the need to demonstrate dissemination in time and dissemination in space and to exclude alternative diagnoses. Although, diagnosis of MS can be made on clinical grounds alone, MRI can support, implement or even replace some clinical criteria. Diagnostic approaches have identify some clinical and paraclinical red flags that should signal particular caution. Many metabolic, vascular, or inflammatory diseases can mimic MS. Few biomarkers, as NMO-IgG, targeting aquaporin-4 or some antibodies directed against central nervous system characterized some specific entities as neuromyelitis optica spectrum disorders or antibody mediated encephalopathies.
10.30 – 12.00

Teaching Course 9Body fluid biomarkers

C. Teunissen (Amsterdam, NL)
M. Khalil (Graz, AT)

Basic introduction to biomarkers in body fluids

C. Teunissen (Amsterdam, NL)

State-of-the-art and opinion on clinical applicability of biomarkers

M. Khalil (Graz, AT)

Role of biomarkers in trials: intelligent treatment design

F. Sellebjerg (Copenhagen, DK)
There is a strong interest in body fluid biomarkers for MS, as these are objective, dynamic and cost effective aids in the diagnosis, prognosis and monitoring of disease progression in MS. Biomarker evaluation needs specific expertise and infrastructure. The BioMS-eu network provides a strong framework to gain expertise in biomarker studies, and the aim of the teaching course is to share and discuss state-of-the-art knowledge of biomarker evaluation. For ECTRIMS 2013 the focus of the course will be on clinical and therapeutic use of –omics data and use of biomarkers in treatment development.
10.30 – 12.00

Teaching Course 10Neuroimmunology in relation to MS pathophysiology and immunotherapy

R. Liblau (Toulouse, FR)
F. Zipp (Mainz, DE)

Activation of the pathogenic immune response in the periphery

R. Liblau (Toulouse, FR)

The blood-CNS barriers and immune cell transmigration into the CNS

B. Engelhardt (Bern, CH)

Effector immune mechanisms within the CNS

F. Zipp (Mainz, DE)
This Teaching Course aims at providing the basic principles on how the immune system can go awry and promote CNS tissue damage in patients with MS. 
In a first lecture, R. Liblau will discuss how an inadequate activation of the adaptive immune response takes place in the periphery. The possible impact of genetic and environmental factors will be discussed. New data begin to identify the antigenic targets of this deleterious response. 
B. Engelhardt will then describe how blood-CNS barriers control the migration of different immune cell subsets into the CNS. She will illustrate the pathways used by immune cells to enter the CNS and introduce the molecules involved.
Finally, F. Zipp will provide an integrated view on the mechanisms by which immune cells induce demyelination and axonal damage and thus represent promising therapeutic targets.
10.30 – 12.00

Teaching Course 11Update in neuroopthalmology

J. de Seze (Strasbourg, FR) 
F. Costello (Calgary, CA)

Optic neuritis

J. de Seze (Strasbourg, FR)

Current concept of neuromyelitis optica and NMO spectrum disorders

A. Jacob (Liverpool, UK)

Optical coherence tomography in the diagnosis and management of optic neuritis and MS

F. Costello (Calgary, CA)
The overall aim of this course is to provide participants with a practical understanding of how the afferent visual system can be used to better understand clinical symptoms and disability progression in MS patients. Recent developments in ocular imaging and visual testing techniques will be discussed in an interactive case-based format. 
At the conclusion of the course, participants will be able to identify how structural damage in the visual pathway can be captured and correlated with other measures of disease activity in MS.
10.30 – 12.00

Teaching Course 12 (MAGNIMS Teaching Course)MRI issues in clinical practice

A. Rovira (Barcelona, ES)
M. Wattjes (Amsterdam, NL)

Use of brain and spinal cord MRI for differential diagnosis

A. Rovira (Barcelona, ES)

How and when should brain and spinal cord MRI be performed in the diagnostic process?

M. Wattjes (Amsterdam, NL)

MRI in predicting treatment response: ready to be used in individual patients?

X. Montalban (Barcelona, ES)
Brain and spinal cord MRI are recognized as the most important paraclinical tool for the diagnosis of MS. MRI is also recognized as a tool for selecting patients for early treatment and monitoring treatment response. The aim of this Teaching Course is to present guidelines on how and when perform brain and spinal cord MRI in the diagnosis and differential diagnosis of MS. In addition, recent data supporting the role of MRI in predicting treatment response will be discussed. All these information is particularly important, as MRI is now integrated in the overall diagnostic scheme of the disease, and in guiding therapeutic decisions including drug safety.
10.30 – 12.00

Teaching Course 13 (MAGNIMS Teaching Course)MRI relevance in neurodegeneration

N. de Stefano (Siena, IT)
C. Enzinger (Graz, AT)

Brain MRI: biomarkers of neurodegeneration

N. de Stefano (Siena, IT)

Spinal cord MRI: biomarkers of neurodegeneration

M. Rocca (Milan, IT)

Imaging of iron accumulation

C. Enzinger (Graz, AT)
While MS is commonly considered as a primarily inflammatory disease, it is increasingly recognised that neurodegenerative process also play a major role in its evolution, in particular with regard to accumulation of permanent tissue damage or disability. This course will be focused on MR-based biomarkers potentially specific for assessing and monitoring neurodegeneration in brain and spinal cord. Recent literature data will be reviewed and the clinical relevance of these results will be considered. Finally, the importance of brain iron accumulation in a disorder such as MS and the MRI-methods able to accurately detect brain iron changes will be discussed.
10.30 – 12.00

Teaching Course 14 (RIMS Teaching Course)Shared decision making to improve treatment decisions

C. Heesen (Hamburg, DE)
A. Solari (Milan, IT)

What is SDM?

V. Entwistle (Aberdeen, UK)

How can SDM be enhanced in MS? Patient-mediated interventions

C. Heesen (Hamburg, DE)

How can SDM be enhanced in MS? Clinician-mediated interventions

A. Solari (Milan, IT)
Shared decision making (SDM) is a process in which clinicians and patients work together to select exams, treatments, and care management based on medical evidence and patients’ preferences and values. It involves the provision of evidence-based information about options, outcomes and uncertainties associated with each option. SDM has great potential to improving patient and clinician satisfaction, and the quality of healthcare. 

By attending this workshop participants will:
- Understand the process of SDM and its importance in effective clinician-patient relationship 
- Explore the challenges that MS clinicians and patients can face in the decision making process 
- Learn techniques that improve clinicians’ skills in involving patients in medical decisions
- Learn techniques that improve patients' understanding of their condition and healthcare choices
Social Program
Registration Not yet available Register Now

Hotel Accommodation

Accommodation in hotels of various price categories in Copenhagen have been reserved.


Official travel agency
Congrex Travel Ltd.
Peter Merian-Strasse 80
4002 Basel / Switzerland
Tel. +41 (0) 61 690 94 11
Fax. +41 (0) 61 690 94 14
Email Opens window for sending
Further Details:

If your hotel reservation is cancelled before 31 July 2013, the deposit will be refunded less € 60.- handling fee.
If your reservation is cancelled after 31 July 2013, or if you arrive later or leave earlier than on the dates indicated on your reservation form, the total accommodation amount will be charged.
Refunds can only be made after the congress if the room is resold (either by Congrex Travel or the hotel).

Scientific Content Up to Date
Scientific Program:
Submission Info

Guidelines for preparation of abstracts

  1. Abstracts may only be submitted online. Abstracts submitted by fax or email will not be accepted.
  2. Abstracts must be submitted in English. Please use UK English spelling.
  3. The presenting author of an accepted abstract must register and attend the congress.
  4. Poster presenters must be present and stand by their posters during their assigned poster sessions
  5. Abstracts should contain only original material not published or presented elsewhere prior to 2 October 2013.
  6. Use a short specific title indicating the nature of the investigation. The background and goals of the study should appear clearly to the reader. The methods and results must contain data, and the conclusions should be clearly expressed.
  7. All abbreviations must be defined the first time they appear in your text (but, do not define in the title).
    Example: Multiple Sclerosis Impact Scale (MSIS), before being used as an abbreviation only.
  8. Avoid complex mathematical formulae. For the symbols ≤ or ≥, type instead <= or >=. For superscript use caret (^) e.g. 10^6 instead of 106. Do not use Greek letters and symbols. Instead of “IFN-γ” use for example “IFN-g” or “IFN-gamma”.
  9. Use generic drug names.
  10. Tables, charts or other graphics may not be included and will be deleted by the editors.
  11. The abstract text may not be longer than 2500 characters including spaces.
  12. Authors should indicate their presentation preference:
    • poster presentation only
    • oral or poster presentation
    "Poster only" implies that your abstract will be considered for poster presentation only and will not be eligible for the poster prize (see corresponding paragraph).
    The Programme Committee reserves the right to decide on the final allocation and presentation method.
  13. A selected number of abstracts will be accepted for oral presentation based on their scientific merits and on their relation to the topics addressed in the scientific programme of the Congress. We therefore encourage submissions on the main topics covered in the scientific programme.
  14. Disclosure of conflict of interest (e.g. grant support, consultancy, membership on advisory councils, speaker’s bureau) and source of funding is mandatory. Each listed author should prepare a one sentence statement to this effect.
  15. The authorship of abstracts reporting results from collaborative research conducted by independent (non-company) investigators and pharmacological company investigators must correctly include independent (academic, clinician and/or scientist) authors.
  16. Please make sure to state your correct e-mail address. After having submitted your abstract, you will receive a confirmation by e-mail with the following information:
    • reference number of your abstract (for correspondence and questions that might arise)
    • your personal user code and password.
    (if you do not receive a confirmation by e-mail please contact the Abstract hotline!)
  17. Should you wish to make corrections to an abstract already submitted or if you wish to submit other abstracts later, you may use your personal access codes. This will shorten the submission procedure.
    Corrections to abstracts can only be made up to the deadline of 21 May 2013.

If you have difficulties in submitting your abstracts or if you need any further information, please contact the 
Abstract Hotline (Monday – Friday during CET business hours): Tel. +41 61 686 77 22.


Authors are requested to select a topic under which they wish their abstract to be reviewed:

Clinical aspects of MS

  1. Diagnosis and differential diagnosis
  2. MS Variants
  3. Paediatric MS
  4. Natural course
  5. Epidemiology
  6. MS and gender
  7. MS symptoms
  8. Clinical assessment tools
  9. Economic burden

Pathology and pathogenesis of MS

  1. Pathology
  2. Inflammation and tissue damage
  3. Experimental models
  4. Genetics /Epigenetics and Pharmacogenetics
  5. Immunology
  6. MS and infections
  7. Environmental risk factors
  8. Neurobiology
  9. Progressive MS
  10. Repairing mechanisms
  1. Imaging
  1. OCT
  1. Neurophysiology
  1. Neuropsychology

Therapy - disease modifying

  1. Immunomodulation/Immunosuppression
  2. Neuroprotection
  3. Long-term treatment monitoring
  4. Risk management for disease modifying treatments
  5. Tools for detecting therapeutic response
  6. Treatment of progressive MS
  7. Others

Therapy - symptomatic

  1. Treatment of specific symptoms
  1. Quality of life
  1. Neuro-ophthalmology
  1. Biomarkers
  1. Chronic cerebro-spinal venous insufficiency (CCVI)
  1. Comprehensive care and rehabilitation (RIMS session)
  2. Neuropsychology and fatigue (RIMS session)
  3. Exercise therapy (RIMS session)
Sponsors Exhibitors
Sponsors / Supporters

The ECTRIMS Organising Committee expresses its thanks and appreciation to all those who are generously contributing to the success of the ECTRIMS 2013.

Organising Agency
Antje Blömeke, Intercom Kongresse GmbH
20249 Hamburg, Germany
+49 48061061
+49 48061066
Event map
Revelant Events